Does caspase inhibition promote clonogenic tumor growth?

Cell Cycle

Volumn 6, Issue 24, 2007, Pages 3048-3053

  Fischer, Ute ^a   Janssen, Katja ^a   Schulze Osthoff, Klaus ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Apaf 1; Apoptosis; Apoptosome; Caspase 9; Clonogenic survival; Taxol; Tumorigenesis

Indexed keywords

APOPTOSIS INDUCING FACTOR; APOPTOSOME; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BCR ABL PROTEIN; CASPASE; CASPASE 9; CASPASE INHIBITOR; CYTOCHROME C; ENDONUCLEASE G; NERVE GROWTH FACTOR; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SURVIVIN;

AMINO ACID SEQUENCE; APOPTOSIS; CANCER CELL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL DEATH; CELL MATURATION; CELL MEMBRANE; CELL SURVIVAL; CLONOGENESIS; ENZYME ACTIVATION; ENZYME INHIBITION; GENE OVEREXPRESSION; MITOCHONDRION; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR GROWTH;

EID: 38149005384     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.24.5118     Document Type: Review

References (61)

1. Danial NN, Korsmeyer SJ. Cell death: Critical control points. Cell 2004; 116:205-19.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
3. Fischer U, Janicke RU, Schulze-Osthoff K. Many cuts to ruin: A comprehensive update of caspase substrates. Cell Death Differ 2003; 10:76-100.
4. Paschen SA, Weber A, Hacker G. Mitochondrial Protein Import: A Matter of Death? Cell Cycle 2007; 23;6(20), [Epub ahead of print].
5. Arnoult D, Gaume B, Karbowski M, Sharpe JC, Cecconi F, Youle RJ. Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated permeabilization. Embo J 2003; 22:4385-99.
6. Salvesen GS, Duckett CS. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3:401-10.
7. Martinou I, Desagher S, Eskes R, Antonsson B, Andre E, Fakan S, Martinou JC. The release of cytochrome c from mitochondria during apoptosis of NGF-deprived sympathetic neurons is a reversible event. J Cell Biol 1999; 144:883-9.
8. Deshmukh M, Johnson Jr EM. Evidence of a novel event during neuronal death: Development of competence-to-die in response to cytoplasmic cytochrome c. Neuron 1998; 21:695-705.
9. Yakovlev AG, Ota K, Wang G, Movsesyan V, Bao WL, Yoshihara K, Faden AI. Differential expression of apoptotic protease-activating factor-1 and caspase-3 genes and susceptibility to apoptosis during brain development and after traumatic brain injury. J Neurosci 2001; 21:7439-46.
10. Deshmukh M, Kuida K, Johnson Jr EM. Caspase inhibition extends the commitment to neuronal death beyond cytochrome c release to the point of mitochondrial depolarization. J Cell Biol 2000; 150:131-43.
11. Sanchis D, Mayorga M, Ballester M, Comella JX. Lack of Apaf-1 expression confers resistance to cytochrome c-driven apoptosis in cardiomyocytes. Cell Death Differ 2003; 10:977-86.
12. Potts MB, Vaughn AE, McDonough H, Patterson C, Deshmukh M. Reduced Apaf-1 levels in cardiomyocytes engage strict regulation of apoptosis by endogenous XIAP. J Cell Biol 2005; 171:925-30.
13. Tran TH, Andreka P, Rodrigues CO, Webster KA, Bishopric NH. Jun kinase delays caspase-9 activation by interaction with the apoptosome. J Biol Chem 2007; 282:20340-50.
14. Schafer ZT, Kornbluth S. The apoptosome: Physiological, developmental, and pathological modes of regulation. Dev Cell 2006; 10:549-61.
15. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70: Anti-apoptotic proteins with tumorigenic properties. Cell Cycle. 2006; 5:2592-601.
16. Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev 2005; 57:187-215.
17. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409:207-11.
18. Baldi A, Santini D, Russo P, Catricala C, Amantea A, Picardo M, Tatangelo F, Botti G, Dragonetti E, Murace R, Tonini G, Natali PG, Baldi F, Paggi MG. Analysis of APAF-1 expression in human cutaneous melanoma progression. Exp Dermatol 2004; 13:93-7.
19. Dai DL, Martinka M, Bush JA, Li G. Reduced Apaf-1 expression in human cutaneous melanomas. Br J Cancer 2004; 91:1089-95.
20. Fujimoto A, Takeuchi H, Taback B, Hsueh EC, Elashoff D, Morton DL, Hoon DS. Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res 2004; 64:2245-50.
21. Zanon M, Piris A, Bersani I, Vegetti C, Molla A, Scarito A, Anichini A. Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents. Cancer Res 2004; 64:7386-94.
22. Jia L, Srinivasula SM, Liu FT, Newland AC, Fernandes-Alnemri T, Alnemri ES, Kelsey SM. Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood 2001; 98:414-21.
23. Fu WN, Bertoni F, Kelsey SM, McElwaine SM, Cotter FE, Newland AC, Jia L. Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. Oncogene 2003; 22:451-5.
24. Furukawa Y, Sutheesophon K, Wada T, Nishimura M, Saito Y, Ishii H, Furukawa Y. Methylation silencing of the Apaf-1 gene in acute leukemia. Mol Cancer Res 2005; 3:325-34.
25. Krepela E, Prochazka J, Liul X, Fiala P, Kinkor Z. Increased expression of Apaf-1 and procaspase-3 and the functionality of intrinsic apoptosis apparatus in nonsmall cell lung carcinoma. Biol Chem 2004; 385:153-68.
26. Krepela E, Prochazka J, Fiala P, Zatloukal P, Selinger P. Expression of apoptosome pathway-related transcripts in nonsmall cell lung cancer. J Cancer Res Clin Oncol 2006; 132:57-68.
27. Deming PB, Schafer ZT, Tashker JS, Potts MB, Deshmukh M, Kornbluth S. Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release. Mol Cell Biol 2004; 24:10289-99.
28. Haga A, Funasaka T, Niinaka Y, Raz A, Nagase H. Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression. Int J Cancer 2003; 107:707-14.
29. Gerhard MC, Zantl N, Weirich G, Schliep S, Seiffert B, Hacker G. Functional evaluation of the apoptosome in renal cell carcinoma. Br J Cancer 2003; 89:2147-54.
30. Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, Lowe SW. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 1999; 284:156-9.
31. Marsden VS, Ekert PG, Van Delft M, Vaux DL, Adams JM, Strasser A. Bcl-2-regulated apoptosis and cytochrome c release can occur independently of both caspase-2 and caspase-9. J Cell Biol 2004; 165:775-80.
32. Marsden VS, Kaufmann T, O'Reilly L A, Adams JM, Strasser A. Apaf-1 and caspase-9 are required for cytokine withdrawal-induced apoptosis of mast cells but dispensable for their functional and clonogenic death. Blood 2006; 107:1872-7.
33. Marsden VS, O'Connor L, O'Reilly LA, Silke J, Metcalf D, Ekert PG, Huang DC, Cecconi F, Kuida K, Tomaselli KJ, Roy S, Nicholson DW, Vaux DL, Bouillet P, Adams JM, Strasser A. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 2002; 419:634-7.
34. Ekert PG, Read SH, Silke J, Marsden VS, Kaufmann H, Hawkins CJ, Gerl R, Kumar S, Vaux DL. Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die. J Cell Biol 2004; 165:835-42.
35. Scott CL, Schuler M, Marsden VS, Egle A, Pellegrini M, Nesic D, Gerondakis S, Nutt SL, Green DR, Strasser A. Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation. J Cell Biol 2004; 164:89-96.
36. Janssen K, Pohlmann S, Janicke RU, Schulze-Osthoff K, Fischer U. Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during taxol treatment. Blood 2007, [Epub ahead of print].
37. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002; 1:289-98.
38. Vogt PK, Bader AG, Kang S. PI 3-kinases: Hidden potentials revealed. Cell Cycle. 2006; 5:946-9.
39. Brady SC, Allan LA, Clarke PR. Regulation of caspase 9 through phosphorylation by protein kinase C zeta in response to hyperosmotic stress. Mol Cell Biol 2005; 25:10543-55.
40. Pathan N, Marusawa H, Krajewska M, Matsuzawa S, Kim H, Okada K, Torii S, Kitada S, Krajewski S, Welsh K, Pio F, Godzik A, Reed JC. TUCAN, an antiapoptotic caspase-associated recruitment domain family protein overexpressed in cancer. J Biol Chem 2001; 276:32220-9.
41. Yamamoto M, Torigoe T, Kamiguchi K, Hirohashi Y, Nakanishi K, Nabeta C, Asanuma H, Tsuruma T, Sato T, Hata F, Ohmura T, Yamaguchi K, Kurotaki T, Hirata K, Sato N. A novel isoform of TUCAN is overexpressed in human cancer tissues and suppresses both caspase-8- and caspase-9-mediated apoptosis. Cancer Res 2005; 65:8706-14.
42. Krajewska M, Kim H, Kim C, Kang H, Welsh K, Matsuzawa S, Tsukamoto M, Thomas RG, Assa-Munt N, Piao Z, Suzuki K, Perucho M, Krajewski S, Reed JC. Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers. Clin Cancer Res 2005; 11:5451-61.
43. Chau BN, Cheng EH, Kerr DA, Hardwick JM. Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1. Mol Cell 2000; 6:31-40.
44. Paydas S, Tanriverdi K, Yavuz S, Disel U, Sahin B, Burgut R. Survivin and aven: Two distinct antiapoptotic signals in acute leukemias. Ann Oncol 2003; 14:1045-50.
45. Choi J, Hwang YK, Sung KW, Kim DH, Yoo KH, Jung HL, Koo HH. Aven overexpression: Association with poor prognosis in childhood acute lymphoblastic leukemia. Leuk Res 2006; 30:1019-25.
46. Pandey P, Saleh A, Nakazawa A, Kumar S, Srinivasula SM, Kumar V, Weichselbaum R, Nalin C, Alnemri ES, Kufe D, Kharbanda S. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. Embo J 2000; 19:4310-22.
47. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev 1999; 13:239-52.
48. Vucic D, Franklin MC, Wallweber HJ, Das K, Eckelman BP, Shin H, Elliott LO, Kadkhodayan S, Deshayes K, Salvesen GS, Fairbrother WJ. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: Implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J 2005; 385:11-20.
49. Zangemeister-Wittke U, Simon HU. An IAP in action: The multiple roles of survivin in differentiation, immunity and malignancy. Cell Cycle 2004; 3:1121-3.
50. Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I, Reed JC. HBXIP functions as a cofactor of survivin in apoptosis suppression. Embo J 2003; 22:2729-40.
51. Cummins JM, Kohli M, Rago C, Kinzler KW, Vogelstein B, Bunz F. X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 2004; 64:3006-8.
52. Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell Death Differ 2006; 13:179-88.
53. Fong WG, Liston P, Rajcan-Separovic E, St Jean M, Craig C, Korneluk RG. Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics 2000; 70:113-22.
54. Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D, Tamai K, Craig CG, McBurney MW, Korneluk RG. Identification of XAF1 as an antagonist of XIAP anti-Caspase activity. Nat Cell Biol 2001; 3:128-33.
55. Shibata T, Mahotka C, Wethkamp N, Heikaus S, Gabbert HE, Ramp U. Disturbed expression of the apoptosis regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas. Diagn Mol Pathol 2007; 16:1-8.
56. Arora V, Cheung HH, Plenchette S, Micali OC, Liston P, Korneluk RG. Degradation of Survivin by the X-linked Inhibitor of Apoptosis (XIAP)-XAF1 Complex. J Biol Chem 2007; 282:26202-9.
57. Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 2007; 46:324-9.
58. Schwerk C, Schulze-Osthoff K. Nonapoptotic functions of caspases in cellular proliferation and differentiation. Biochem Pharmacol 2003; 66:1453-8.
59. Spencer SL, Gerety RA, Pienta KJ, Forrest S. Modeling somatic evolution in tumorigenesis. PLoS Comput Biol 2006; 2:e108.
60. Blagosklonny MV. Why therapeutic response may not prolong the life of a cancer patient: Selection for oncogenic resistance. Cell Cycle 2005; 4:1693-8.
61. Tanaka N, Moriya K, Kiyosawa K, Koike K, Aoyama T. Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor alpha in transgenic mice: Implications for HCV-associated hepatocarcinogenesis. Int J Cancer 2007, [Epub ahead of print].